TAMPA, Fla. (March 13, 2018) – Drug therapies that target a specific molecule have changed the way patients are treated for cancer and greatly improved survival rates. However, some patients do not respond to these therapies because the drug is not reaching the tumor cells effectively. In a new study published in Scientific Reports, Moffitt Cancer Center researchers combined single-cell imaging of cancer cells in mice with mathematical modeling to determine which drug characteristics are the most important for efficient drug uptake.
One of the inherent problems with targeted therapies is that tumors and their surrounding environment are complex and heterogeneous. Not all cells in a given tumor are alike. They can differ from one another in the expression of the targeted membrane receptors which may result in inadequate uptake and non-uniform response to the targeting drug. Additionally, the surrounding tumor environment is composed of different cell types with different properties and densities that can impact the ability of a drug to be effective.
These variations make it difficult to develop drugs that can effectively target all of the cells in a tumor. Furthermore, these cellular and genetic differences may cause a patient to be unresponsive to a cancer-targeted drug because some tumor cells may not be fully exposed to the drug and this incomplete exposure may enable these cells to develop drug resistance.
"Clinical success or failure of targeted therapy depends heavily on whether the drug molecules are able to reach all tumor cells and engage with their molecular targets to invoke the desired therapeutic effect," said Kasia A. Rejniak, Ph.D., associate member of the Department of Integrated Mathematical Oncology at Moffitt. This work was accomplished through collaboration between Rejniak computational group and the laboratory group of Morse, Ph.D., associate member of the Department of Cancer Physiology.
The standard methods that scientists use to study drug uptake are based on the idea that a tumor and its surroundings have uniform characteristics. However, this assumption is inaccurate and may lead to a one-size-fits-all approach to treatment. The Moffitt research team wanted to take a different approach to study drug uptake. They used mathematical modeling and imaging techniques that allowed them to track and predict the ability of a single cell to take up a drug. Within their model, they compared different drug characteristics and tumor properties to determine which conditions lead to more effective drug uptake by a cell.
They discovered that the amount of drug that binds to a cell is dependent on how quickly a drug diffused through the tissue rather than on the concentration of drug that enters the tissue. Drugs that diffused quickly tended to bind more effectively to cells that were further away from blood vessels. Alternatively, drugs that diffused slowly tended to bind to cells that were closer to blood vessels and were more effective when the cells were tightly packed. The researchers also showed that drugs that are released quickly are able to bind more effectively to cells with different levels of drug receptors.
These discoveries suggest that changing different properties of a drug or the way a drug is administered may lead to increased delivery to tumor cells. “For example, to treat the fast-growing cells located near the vasculature, slowly diffusing agents may be beneficial. In contrast, for the dormant cells in poorly vascularized regions, the highly mobile agents may be preferential, or in some cancers, local injection directly to the tumor site may be beneficial,” explained Rejniak. Ultimately, the researchers hope that their approach could eventually be used to design more personalized treatment options for cancer patients.
The study was supported by funds from the American Cancer Society and the National Institutes of Health.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 49 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt is a Top 10 cancer hospital and has been nationally ranked by U.S. News & World Report since 1999. Moffitt devotes more than 2 million square feet to research and patient care. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 5,700 team members, Moffitt has an economic impact in the state of $2.1 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter and YouTube.